PRVB - Intravacc's vaccine candidate developed for Provention Bio enters human Phase I clinical study

Intravacc, leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B vaccine it developed and manufactured for Provention Bio ([[PRVB]] -0.1%) in less than 36 months, has entered into a first in human Phase I clinical study called PROVENT (PROtocol for coxsackievirus Vaccine in healthy volunteers).Provention Bio is clinical stage biopharmaceutical company, that selected Intravacc in 2018 to lead product development and manufacturing of clinical study material for Provention's vaccine candidate.PROVENT is a placebo-controlled, double-blind, randomized Phase I first-in-human clinical study being conducted at the Clinical Research Services Turku - CRST Oy, a clinical trial unit in Turku, Finland.Results of PROVENT are expected in 2H21.

For further details see:

Intravacc's vaccine candidate developed for Provention Bio enters human Phase I clinical study